Seeking Alpha
View as an RSS Feed

Rich Steffens  

View Rich Steffens' Comments BY TICKER:
Latest  |  Highest rated
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    The AE37 breast cancer study is the only active study being funded. The H5N1 Phase I was completed a few years ago. The prostate cancer Phase I was also completed a couple of years ago, with new positive 3 year immunological data presented at ASCO's 2013 Annual Meeting. A Phase II protocol is set, but that study won't begin until there's funding. So, when the 10K states that +75% of research expenses are for Antigen, they mean for the Phase II in breast cancer, since that's the only active study. The 10Q filed in Dec illustrates the reduced costs due to their belt tightening:

    "The decrease in general and administrative expenses is related to a decrease in professional services expenses, including legal and consulting services of approximately $256,000, in addition to a decrease in payroll related expenses of approximately $38,000 and a decrease in office related expenses of approximately $43,000 in the quarter ended October 31, 2013, as compared to the previous year quarter ended October 31, 2012. We also incurred reductions of expenses in most other categories due to efforts to conserve cash until we complete the strategic development plan announced by management on March 30, 2011."

    The 10KA, filed in Oct 2013, shows an example of reduced salaries, such as for the CEO:

    " Effective October 1, 2011, Mr. Fletcher agreed to defer a portion of his salary and Mr. Fletcher’s base salary was reduced from $475,000 to $275,000 as of that date. On June 6, 2013, the Company granted Mr. Fletcher 1,587,300 options in full and final payment of obligations to pay Mr. Fletcher’s deferred salary amount covering the period from April 1, 2013 to June 30, 2013. On April 1, 2013, the Company granted Mr. Fletcher 5,143,787 options in full and final payment of obligations to pay Mr. Fletcher’s deferred salary amount covering the period from June 1, 2012 to March 31, 2013. On June 19, 2012, the Company granted Mr. Fletcher 1,457,195 options in full and final payment of obligations to pay Mr. Fletcher’s deferred salary amount covering the period from October 1, 2011 to May 31, 2012. All of the aforementioned options were issued in lieu of cash payment of deferred compensation owing."

    The CEO said as much in a quote within my article. "As we've noted publicly, our scarce economic resources have recently been focused on supporting the AE37 breast cancer vaccine." And yes, they need a partner to fund a Phase III, as they note, to fund a Phase III study.
    Jan 26, 2014. 12:55 PM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Odd, not all of my replies are showing, but I think they show here:

    http://seekingalpha.co...
    Jan 26, 2014. 11:59 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    I tried to respond Raul, but the comment section is acting odd. I think there may have been profit taking after a strong run over the last month.
    Jan 26, 2014. 11:52 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Thanks Beasley!
    Jan 26, 2014. 11:08 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Thanks Roul. I'm not sure, but GALE had a remarkable run, so perhaps some selling occurred as a result of CNBC's Jim Cramer saying to ring the register.
    Jan 26, 2014. 11:07 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Hi CJSantimays,

    That remains to be seen, since the company is holding back on a spinout, so we don't know any terms or what the valuation of Antigen Express will be in that timeframe. The company has announced a plan to award GNBT shareholders of record a dividend based upon the amount of GNBT shares they hold. They had also stated intent to award another dividend based on how many GNBT shares a shareholder still holds at a certain time point post the spinout. Generex would remain the largest holder of Antigen stock, so GNBT shareholders would still have that AE value in their GNBT shares, beyond the new AE shares awarded as dividends. This remains fluid, and we can learn more during the Generex Annual Meeting in the Spring.
    Jan 26, 2014. 11:05 AM | 1 Like Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Hi Tom,

    As far as HLA restricted, perhaps this posting from a breast cancer forum can help. Look at the post by TectonicShift on Nov 6, 2012 at 07:04 am:

    http://bit.ly/1aXQwIS
    Jan 26, 2014. 10:57 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    thank you!
    Jan 26, 2014. 10:47 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Did you call me a Big Dip? lol.
    Jan 26, 2014. 10:21 AM | 1 Like Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Hi Tom,

    I believe that Dr. Craig Eagle of Pfizer still serves on the Antigen Express Scientific Advisory Board.
    Jan 26, 2014. 10:18 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Thanks realaboo!
    Jan 26, 2014. 10:14 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    I don't think GALE would be the one to do a deal with Antigen Express, unless it was to create a multi-epitope vaccine using AE37 with NeuVax, as Dr. Mittendorf's team has written about, to make NeuVax more potent and longer lasting. The longer lasting part is because AE37 stimulates CD4+ T Cells, which are the memory, as well as CD8+ killer T Cells. However, Antigen Express is already studying a doublet peptide vaccine where AE37 is combined with the GP2 vaccine, a MHC Class I vaccine like NeuVax, in a Phase I study being funded by the Mary Crowley Cancer Center.
    Jan 26, 2014. 10:12 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Thanks chongkim!
    Jan 26, 2014. 10:06 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    The added diagnostic test would be to see if the cancer patient would benefit from the NeuVax vaccine, since the vaccine is restricted to specific allele types. This added diagnostic test wouldn't be needed for AE37, so the potential market reach for AE37 is all low HER2 patients, as opposed to a subgroup. Early stage breast cancer isn't rare, but a large market representative of a medical unmet need for targeted treatment. Currently, there is no treatment option.
    Jan 26, 2014. 10:06 AM | Likes Like |Link to Comment
  • Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer [View article]
    Thanks runebase!
    Jan 26, 2014. 09:58 AM | Likes Like |Link to Comment
COMMENTS STATS
203 Comments
287 Likes